🔎 Trials Near Me

Akèy › Hidradénite suppurative

Etid klinik pou Hidradénite suppurative ap rekrite nan Etazini

29 etid pou Hidradénite suppurative ap rekrite patisipan nan sit atravè Etazini.

Vil ki gen plis etid

Pa eta

Etid ki fèk mete ajou

Tèks ofisyèl etid la (Anglè)

An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS

Ap rekriteFaz 3
Laj 18 a 100 · Tout sèks · Mizajou Sep 28, 2026 · NCT07665437

ORKA-002 Versus Placebo in Participants With Moderate-to-Severe Hidradenitis Suppurativa

Ap rekriteFaz 2
Laj 18 a 79 · Tout sèks · Mizajou Sep 24, 2026 · NCT07783542

Safety and Efficacy of Soquelitinib in Adults With Hidradenitis Suppurativa

Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 22, 2026 · NCT07828860

Regulation of Inflammatory Genes in Hidradenitis Suppurativa

Ap rekriteEtid obsèvasyon
Laj 18 a 89 · Tout sèks · Mizajou Sep 21, 2026 · NCT05507125

Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib

Ap rekriteFaz 3
Laj 18 ak plis · Tout sèks · Mizajou Sep 15, 2026 · NCT06855498

Targeting Nociceptors in Hidradenitis Suppurativa

Ap rekriteEtid obsèvasyon
Laj 18 a 75 · Tout sèks · Mizajou Sep 10, 2026 · NCT05403710

Capsule Microbiota Transplant Therapy for Hidradenitis Suppurativa

Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06058520

Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.

Ap rekriteFaz 1 bonè
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT06326476

Brivekimig for the Treatment of Moderate to Severe Hidradenitis Suppurativa

Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT07170917

A Study to Assess NAV-240 in Adult Participants With Hidradenitis Suppurativa

Ap rekriteFaz 2
Laj 18 a 70 · Tout sèks · Mizajou Jul 22, 2026 · NCT07384975

Myriad™ Augmented Soft Tissue Reconstruction Registry

Ap rekriteEtid obsèvasyon
Laj 18 ak plis · Tout sèks · Mizajou Jul 15, 2026 · NCT05243966

The Safety and Efficacy of Roflumilast Foam in HS

Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Jul 9, 2026 · NCT07263230

A Study Evaluating BFB759 in Moderate to Severe Hidradenitis Suppurativa

Ap rekriteFaz 2/3
Laj 18 a 75 · Tout sèks · Mizajou May 29, 2026 · NCT07287644

Pelashield™ PainGuard™ vs Restrata® in HS Surgery

Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 22, 2026 · NCT07316192

Radiotherapy for Refractory Hidradenitis Suppurativa

Ap rekrite
Laj 18 ak plis · Tout sèks · Mizajou May 15, 2026 · NCT07414550

Clinical and Biological Characteristics of Hidradenitis Suppurativa

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 13 ak plis · Tout sèks · Mizajou May 4, 2026 · NCT03967600

Hidradenitis Suppurativa Prospective Observational Registry and Biospecimen Repository

Ap rekriteEtid obsèvasyon
Laj 10 ak plis · Tout sèks · Mizajou Apr 29, 2026 · NCT04115566

A Study of Zasocitinib in Adults With Hidradenitis Suppurativa

Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Mar 6, 2026 · NCT07244263

The Ohio State University Dermatology Biorepository

Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Tout laj · Tout sèks · Mizajou Feb 27, 2026 · NCT03146676

A Study for Evaluating Safety & Efficacy of Topical Roflumilast 0.3% Foam in Hidradenitis Suppurativa

Ap rekriteFaz 2
Laj 18 a 90 · Tout sèks · Mizajou Dec 23, 2025 · NCT07077902

Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.